Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript
Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.
Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript
Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Viatris (VTRS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva Vs. Viatris: Who Will Dominate In President Trump's America?
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA-approved drugs and product candidates relative to the rival. By reading this article, you will learn which stock, Viatris or Teva, is more attractive in the long term.
Viatris: Indore Plant Could Boost 2026 Numbers
Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recovery in 2026 could lead to earnings beats versus consensus estimates. Despite capital returns, persistent sales declines and lack of progress in debt reduction raise concerns about VTRS's long-term investment viability.
